Acute Graft Versus Host Disease - 162 Studies Found
| Completed |
: Anti Cytokine Combination Therapy With Daclizumab and Infliximab for Treatment of Steroid Refractory Acute GVHD : Graft vs Host Disease : 2007-12-14 : Drug: daclizumab, infliximab Daclizumab 1 mg/kg IV days 1, 4, 8, 15 and 22. Infliximab 10 mg/kg IV days |
| No longer available |
: Prochymal® Expanded Access for Adults Who Have Failed Steroid Treatment for Acute GVHD : Graft-Versus-Host Disease : 2009-01-19 : Drug: Prochymal® Patients will be treated with Prochymal twice per week at a dose of 2 x 106 hMSC/k |
| Completed |
: Safety and Efficacy of Prochymal for the Salvage of Treatment-Refractory Acute GVHD Patients : Graft Versus Host Disease : 2006-01-31 : Drug: Prochymal (TM) |
| No longer available |
: Prochymal Expanded Access Treatment for Pediatric Patients Who Have Failed Steroids for Acute GVHD :
: 2008-09-23 : Biological: remestemcel-L Patients will be treated with Prochymal® twice per week at a dose of 2 x |
| Recruiting |
: Donor Atorvastatin Treatment in Preventing Severe Acute GVHD After Nonmyeloablative Peripheral Blood Stem Cell Transplant in Patients With Hematological Malignancies :
|
| Completed |
: Study of MEDI 507 in the Treatment of Pediatric Patients : Graft Versus Host Disease : 2008-12-19 :
|
| Completed |
: Dose Study of Antithymocyteglobulin in Haploidentical Allogeneic Stem Cell Transplantation : Hematopoietic Stem Cell Transplantation : 2015-12-29 : Drug: ATG ATG will be intravenously infused via a central venous catheter in 3 or 4 days, from day -4 or |
| Completed |
: BMT Auto MSCs GvHD Ph 1 :
: 2015-02-05 : Biological: Autologous mesenchymal stromal cells (MSCs) Infusion of MSCs delivered to each patient will |
| Completed |
: Donor Regulatory T Cells Infusion in Patients With Chronic Graft-versus-host Disease (GVHD) :
|
| Completed |
: Acute Graft-versus-Host Disease Treatment (BMT CTN 0802) :
: 2009-10-23 :
|